Surrozen Inc Ordinary Shares SRZN
News
Surrozen to Present at Upcoming Healthcare Investor Conference
Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million
Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
Surrozen to Present at Upcoming Healthcare Investor Conferences
